First-Line Market For Melanoma Not A Lock For Bristol Or Roche
This article was originally published in The Pink Sheet Daily
Executive Summary
Data on Bristol's recently approved Yervoy and Roche's recently submitted vemurafenib show remarkable advances for melanoma but also establish competing options for first-line therapy.
You may also be interested in...
GlaxoSmithKline Deals One-Two Punch With BRAF/MEK Pair
GSK presented Phase III results for its BRAF inhibitor dabrafenib and its MEK inhibitor trametinib at the American Society of Clinical Oncology annual meeting June 4. But the real excitement is over the just-starting Phase III trial combining the two drugs.
Bristol/Roche Finally Start Combination Melanoma Trial
The drug makers, potential competitors, will study Bristol's CTLA-4 inhibitor Yervoy in combination with Roche's investigational BRAF inhibitor vemurafenib in metastatic melanoma.
Roche's Vemurafenib Filed With Companion Diagnostic In Tow
Roche/Genentech seeks priority review and broad indication in metastatic melanoma for ground-breaking BRAF inhibitor.